Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia
Mohana et al.
, Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi..
, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.031 (date from earlier preprint)
Safety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and has minimal side effects. No ICU admission or deaths were reported.
Mohana et al., 17 Oct 2020, peer-reviewed, 15 authors.
Abstract: International Journal of Infectious Diseases 102 (2021) 110–114
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier.com/locate/ijid
Hydroxychloroquine safety outcome with an approved
therapeutic protocol for COVID-19 outpatients in Saudi Arabia
Abdulrhman Mohanaa,* , Tarek Sulaimanb , Nagla Mahmoudc , Mustafa Hassaneinc,
Amel Alfaiﬁc , Eissa Alenazic , Nashwa Radwanc, Nasser AlKhalifahb , Ehab Elkadyc ,
Abdullah Almohaizeied, Fouad AboGazalahc , Khaled AlabdulKareemc , Fahad AlGhofailib ,
Hani Jokhdare , Fahad Alrabiahd
Saudi Centre for Disease Prevention and Control, 70 SCDC Building, Al Aarid, King Abdulaziz Rd, Riyadh 13354, Saudi Arabia
King Fahad Medical City, 59046 Riyadh 11525, Saudi Arabia
Assisting Deputyship for Primary Health Care, Ministry of Health, 11176 Riyadh, Saudi Arabia
King Faisal Specialist Hospital and Research Centre, Zahrawi St, Al Maath, Al Maazer, Riyadh 12713, Saudi Arabia
Deputyship of Public Health, Ministry of Health, 11176 Riyadh, Saudi Arabia
A R T I C L E I N F O
A B S T R A C T
Received 20 August 2020
Received in revised form 7 October 2020
Accepted 10 October 2020
Background: Global health has been challenged by the COVID-19 pandemic since late 2019. Multiple
approaches have been applied to relieve pressure on and support existing healthcare. The Saudi Arabian
Ministry of Health (MOH) launched an initiative to support the national healthcare system. Since 5 June
2020, 238 outpatient fever clinics have been established nationwide. This study aimed to assess the safety
outcome and reported adverse events from hydroxychloroquine use among suspected COVID-19 patients.
Methods: The cross-sectional study included 2733 patients subjected to the MOH treatment protocol
(hydroxychloroquine) and followed up for 3–7 days after initiation. Data were collected through an
electronic link and cross-checked with the national database (Health Electronic Surveillance Network) and
reports from the MOH Morbidity and Mortality Committee.
Results: Two hundred and forty patients (8.8%) discontinued treatment because of side effects (4.1%) and
non-clinical reasons (4.7%). Adverse effects were reported among 6.7% of all participants, including mainly
cardiovascular symptoms (2.5%; 0.15% with corrected QT prolongation) and gastrointestinal symptoms
(2.4%). No intensive care unit admission or death was reported among these patients.
Conclusion: Our results show that hydroxychloroquine use for COVID-19 patients with mild to moderate
symptoms in an outpatient setting with the recommended protocol and inclusion/exclusion criteria is safe,
is highly tolerable and has minimal side effects.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
COVID-19 has rapidly emerged as a pandemic viral infection
that has caused signiﬁcant morbidity and death worldwide. Global
* Corresponding author.
E-mail addresses: email@example.com, firstname.lastname@example.org
(A. Mohana), email@example.com (T. Sulaiman), firstname.lastname@example.org
(N. Mahmoud), email@example.com (M. Hassanein), amhalfaiﬁ@moh.gov.sa
(A. Alfaiﬁ), firstname.lastname@example.org (E. Alenazi),..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.